TRERF1 and neuromuscular disease caused by qualitative or quantitative defects of alpha-dystroglycan: Importantly, we also observed a significant decrease in the fibrotic area of RAPA KO compared to VEH KO diaphragms (Fig. 6a, b), demonstrating the therapeutic potential of RAPA treatment for dystroglycanopathies.